ArticleCell death discovery2024
CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer.
Abstract read
In one paragraph
Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Effect of xeroderma pigmentosum group C on the characteristics and regulatory mechanisms of lung cancer stem cells.International journal of oncology · 2026Article
- Dual targeting of SLC6A14 and autophagy/macropinocytosis enhances therapeutic efficacy in pancreatic ductal adenocarcinoma.The Biochemical journal · 2026Article
- Multiple Regulatory Mechanisms of Post-Translational Modifications and Therapeutic Potential of Mitotic Catastrophe.International journal of molecular sciences · 2026Review
- Copper-rhein nanozymes induce bacterial activation-exhaustion death for the treatment of bacterial pneumonia and infected wounds.Journal of nanobiotechnology · 2026Article
- Article
- Taguchi optimisation of ZnO and GO-integrated HA nanocomposite with improved antibacterial performance.Scientific reports · 2026Article
- Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications.Frontiers in oncology · 2026Review
- CHK1 as a Metabolic and Immunological Regulator: Implications for Cancer Therapy.Oncology research · 2026Review
- PARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer.Frontiers in immunology · 2026Review
- Role of Poly (ADP-Ribose) Polymerase-1 (PARP1) and Its Inhibitors for Cancer Therapy.Mini reviews in medicinal chemistry · 2026Review
- Phlorotannins fromMarine drugs · 2025Article
- Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities.Cancers · 2025Review
- Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis.NAR cancer · 2025Article
- Pan-cancer NK cell-related immunotherapy signatures for predicting PD-1 treatment response.Medicine · 2025Article
- Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment.Cancer cell international · 2025Review
- Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.Cancer immunology, immunotherapy : CII · 2025Article
- ARHGAP11A, a member of Rho GTPase activating protein family, as a prognostic biomarker linked to DNA damage response across pan-cancer.BMC cancer · 2025Article
- Targeting Skp2 by Tanshinone IIA overcomes chemoresistance in colorectal cancer.Cell biology and toxicology · 2025Article
- Ciprofol suppresses glycolysis and EMT in colorectal cancer cells by activating APC to modulate the Wnt/β-catenin signaling pathway.Scientific reports · 2025Article
- Analysis of factors influencing lung cancer in patients with type 2 diabetes mellitus.Medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Ganesh AcharyaDepartment of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Chinnadurai ManiDepartment of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Naresh SahDepartment of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Karunakar SaamarthyDepartment of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Robert YoungDepartment of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Mark B ReedyDepartment of Obstetrics & Gynecology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.ORCID http://orcid.org/0000-0001-5736-193X
Robert W SobolDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, & Legorreta Cancer Center, Brown University, Providence, RI, USA.
Komaraiah PalleDepartment of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. komaraiah.palle@ttuhsc.edu.ORCID http://orcid.org/0000-0002-3182-0162
Funding
TR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2012 to 2024
$17.3MA Systems Approach to Mapping the DNA Damage ResponseR01ES014811 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2005 to 2021
$8.6MResearch Project 3P01ES028949 · NIEHS · FLORIDA GULF COAST UNIVERSITY · PI PARSONS, MICHAEL, SOBOL, ROBERT W · 2018 to 2024
$3.8MInvestigating genetic ancestry influences on oral cavity and laryngeal cancer survival disparitiesR01CA238061 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAGIN, CAMILLE C., SOBOL, ROBERT W · 2019 to 2023
$3.4MMeasuring genomic DNA damage and DNA repair capacity in longitudinal population samples - a step towards precision preventionU01ES029518 · NIEHS · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2018 to 2022
$2.7MHedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrenceR01CA219187 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PALLE, KOMARAIAH · 2018 to 2023
$2.6MBarcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variabilityR44ES032522 · NIEHS · AMELIA TECHNOLOGIES, LLC · PI GEORGE, JAY, SOBOL, ROBERT W · 2021 to 2023
$1.9MThe Paternal Age Effect - Enhanced Germ Cell Mutagenesis Modulated by the TRP53/APE1/MDM2 Tumor Suppressor AxisR01AG069740 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KRAIG, ELLEN · 2020 to 2024
$1.8MSON-mediated RNA splicing in glioblastomaR01CA236911 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHN, ERIN EUN-YOUNG · 2020 to 2024
$1.8MNCI NIH HHS R01 CA219187NCI NIH HHS R01 CA236911NCI NIH HHS R01 CA238061NIA NIH HHS R01 AG069740NIEHS NIH HHS P01 ES028949NIEHS NIH HHS R01 ES014811NIEHS NIH HHS R44 ES032522NIEHS NIH HHS U01 ES029518NIGMS NIH HHS P41 GM103504NSF | BIO | Division of Environmental Biology (DEB) 1841811U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA238061U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) ES014811U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) ES028949U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) ES029518U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) ES032522U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG069740U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA219187U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA236911
Abstract
Chemoresistance contributes to the majority of deaths in women with ovarian cancer (OC). Altered DNA repair and metabolic signaling is implicated in mediating therapeutic resistance. DNA damage checkpoint kinase 1 (CHK1) integrates cell cycle and DNA repair in replicating cells, and its inhibition causes replication stress, repair deficiency and cell cycle dysregulation. We observed elevated Poly-ADP-ribosylation (PAR) of proteins (PARylation) and subsequent decrease in cellular NAD
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.